Procedural Generation and Rendering of Realistic, Navigable Forest Environments: An Open-Source Tool

Simulation of forest environments has applications from entertainment and art creation to commercial and scientific modelling. Due to the unique features and lighting in forests, a forest-specific simulator is desirable, however many current forest simulators are proprietary or highly tailored to a particular application. Here we review several areas of procedural generation and rendering specific to forest generation, and utilise this to create a generalised, open-source tool for generating and rendering interactive, realistic forest scenes. The system uses specialised L-systems to generate trees which are distributed using an ecosystem simulation algorithm. The resulting scene is rendered using a deferred rendering pipeline, a Blinn-Phong lighting model with real-time leaf transparency and post-processing lighting effects. The result is a system that achieves a balance between high natural realism and visual appeal, suitable for tasks including training computer vision algorithms for autonomous robots and visual media generation.Comment: 14 pages, 11 figures. Submitted to Computer Graphics Forum (CGF). The application and supporting configuration files can be found at https://github.com/callumnewlands/ForestGenerato

An embarrassingly simple approach for visual navigation of forest environments

Navigation in forest environments is a challenging and open problem in the area of field robotics. Rovers in forest environments are required to infer the traversability of a priori unknown terrains, comprising a number of different types of compliant and rigid obstacles, under varying lighting and weather conditions. The challenges are further compounded for inexpensive small-sized (portable) rovers. While such rovers may be useful for collaboratively monitoring large tracts of forests as a swarm, with low environmental impact, their small-size affords them only a low viewpoint of their proximal terrain. Moreover, their limited view may frequently be partially occluded by compliant obstacles in close proximity such as shrubs and tall grass. Perhaps, consequently, most studies on off-road navigation typically use large-sized rovers equipped with expensive exteroceptive navigation sensors. We design a low-cost navigation system tailored for small-sized forest rovers. For navigation, a light-weight convolution neural network is used to predict depth images from RGB input images from a low-viewpoint monocular camera. Subsequently, a simple coarse-grained navigation algorithm aggregates the predicted depth information to steer our mobile platform towards open traversable areas in the forest while avoiding obstacles. In this study, the steering commands output from our navigation algorithm direct an operator pushing the mobile platform. Our navigation algorithm has been extensively tested in high-fidelity forest simulations and in field trials. Using no more than a 16 × 16 pixel depth prediction image from a 32 × 32 pixel RGB image, our algorithm running on a Raspberry Pi was able to successfully navigate a total of over 750 m of real-world forest terrain comprising shrubs, dense bushes, tall grass, fallen branches, fallen tree trunks, small ditches and mounds, and standing trees, under five different weather conditions and four different times of day. Furthermore, our algorithm exhibits robustness to changes in the mobile platform’s camera pitch angle, motion blur, low lighting at dusk, and high-contrast lighting conditions

Effect of angiotensin-converting enzyme inhibitor and angiotensin receptor blocker initiation on organ support-free days in patients hospitalized with COVID-19

IMPORTANCE Overactivation of the renin-angiotensin system (RAS) may contribute to poor clinical outcomes in patients with COVID-19. Objective To determine whether angiotensin-converting enzyme (ACE) inhibitor or angiotensin receptor blocker (ARB) initiation improves outcomes in patients hospitalized for COVID-19. DESIGN, SETTING, AND PARTICIPANTS In an ongoing, adaptive platform randomized clinical trial, 721 critically ill and 58 non–critically ill hospitalized adults were randomized to receive an RAS inhibitor or control between March 16, 2021, and February 25, 2022, at 69 sites in 7 countries (final follow-up on June 1, 2022). INTERVENTIONS Patients were randomized to receive open-label initiation of an ACE inhibitor (n = 257), ARB (n = 248), ARB in combination with DMX-200 (a chemokine receptor-2 inhibitor; n = 10), or no RAS inhibitor (control; n = 264) for up to 10 days. MAIN OUTCOMES AND MEASURES The primary outcome was organ support–free days, a composite of hospital survival and days alive without cardiovascular or respiratory organ support through 21 days. The primary analysis was a bayesian cumulative logistic model. Odds ratios (ORs) greater than 1 represent improved outcomes. RESULTS On February 25, 2022, enrollment was discontinued due to safety concerns. Among 679 critically ill patients with available primary outcome data, the median age was 56 years and 239 participants (35.2%) were women. Median (IQR) organ support–free days among critically ill patients was 10 (–1 to 16) in the ACE inhibitor group (n = 231), 8 (–1 to 17) in the ARB group (n = 217), and 12 (0 to 17) in the control group (n = 231) (median adjusted odds ratios of 0.77 [95% bayesian credible interval, 0.58-1.06] for improvement for ACE inhibitor and 0.76 [95% credible interval, 0.56-1.05] for ARB compared with control). The posterior probabilities that ACE inhibitors and ARBs worsened organ support–free days compared with control were 94.9% and 95.4%, respectively. Hospital survival occurred in 166 of 231 critically ill participants (71.9%) in the ACE inhibitor group, 152 of 217 (70.0%) in the ARB group, and 182 of 231 (78.8%) in the control group (posterior probabilities that ACE inhibitor and ARB worsened hospital survival compared with control were 95.3% and 98.1%, respectively). CONCLUSIONS AND RELEVANCE In this trial, among critically ill adults with COVID-19, initiation of an ACE inhibitor or ARB did not improve, and likely worsened, clinical outcomes. TRIAL REGISTRATION ClinicalTrials.gov Identifier: NCT0273570